{"_meta":{"attribution":"Data aggregated by pdata.world (https://pdata.world) from Polymarket, Kalshi, Manifold, Myriad, Limitless, Predict, Opinion and Gemini; CC BY 4.0; source data © each venue.","canonical_url":"https://pdata.world/events/kalshi/KXTOZORAKIMAB-27","as_of":"2026-11-21T02:04:29.985974Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Kalshi): \"FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)\" — 81% as of 2026-11-20 UTC. https://pdata.world/events/kalshi/KXTOZORAKIMAB-27","source_url":"https://kalshi.com/markets/kxtozorakimab/fda-decision-tozorakimab-by-astrazeneca-on-or-before-march-31-2027/kxtozorakimab-27","data_as_of":"2026-11-20T20:47:01.357418Z","full_record":"https://api.pdata.world/api/v1/events/kalshi/KXTOZORAKIMAB-27","price_history":"https://api.pdata.world/api/v1/events/kalshi/KXTOZORAKIMAB-27/history?range=7d&limit=20"},"kind":"live","venue":"Kalshi","source":"kalshi","id":"KXTOZORAKIMAB-27","title":"FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)","status":"open","categories":["Finance"],"countries":["United States"],"closes_at":"2027-04-01T14:00:00Z","outcomes_are":"one market","volume_24h":121.88,"volume_total":430.81,"volume_unit":"contracts, as Kalshi reports them","outcomes_total":1,"outcomes":[{"name":"a full approval or an accelerated approval","probability":0.81,"change_24h":0.08,"volume_24h":121.88,"market_id":"KXTOZORAKIMAB-27-Y"}],"rules":"If the FDA's decision on Tozorakimab by AstraZeneca on or before March 31, 2027 is a full approval or an accelerated approval, the market resolves to Yes.\n\n---\n\nThis market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.","rules_apply_to":"the event's only market"}